These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31118141)

  • 21. Chemotherapy response score as a prognostic tool in patients with advanced stage endometrial carcinoma treated with neoadjuvant chemotherapy.
    Jani I; Lastra RR; Brito KS; Liao C; Lazo I; Lee NK; Yamada SD; Kurnit KC
    Int J Gynecol Cancer; 2021 Jun; 31(6):852-858. PubMed ID: 33833085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathologic chemotherapy response score in epithelial ovarian cancer: Surgical, genetic, and survival considerations.
    Barrington DA; Felix AS; Owda R; Suarez AA; Cohen DW; Senter L; Copeland LJ; Fowler JM; Backes FJ; Cohn DE; Bixel KL; O'Malley DM; Salani R; Cosgrove CM
    Surg Oncol; 2020 Sep; 34():40-45. PubMed ID: 32891351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The added value of CA125 normalization before interval debulking surgery to the chemotherapy response score for the prognostication of ovarian cancer patients receiving neoadjuvant chemotherapy for advanced disease.
    Liang WF; Wang LJ; Li H; Liu CH; Wu MF; Li J
    J Cancer; 2021; 12(3):946-953. PubMed ID: 33403051
    [No Abstract]   [Full Text] [Related]  

  • 24. Poor Prognostic Factors in Patients Undergoing Surgery After Neoadjuvant Chemotherapy for Ovarian, Tubal, or Peritoneal Cancer.
    Kaban A; Topuz S; Saip P; Sozen H; Celebi K; Salihoglu Y
    J Obstet Gynaecol Can; 2017 Dec; 39(12):1163-1170. PubMed ID: 28784563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy-associated foam cell aggregates as a prognostic factor in patients with pelvic high-grade serous carcinoma receiving neo-adjuvant chemotherapy.
    Kojima N; Kuno I; Ushigusa T; Kato T; Yoshida H
    Virchows Arch; 2020 Sep; 477(3):429-436. PubMed ID: 32103350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of the peritoneal tumor microenvironment on invasion of peritoneal metastases of high-grade serous ovarian cancer and the impact of NEOADJUVANT chemotherapy.
    van Baal JOAM; Lok CAR; Jordanova ES; Horlings H; van Driel WJ; Amant FC; Van de Vijver KK
    Virchows Arch; 2020 Oct; 477(4):535-544. PubMed ID: 32179982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
    Aghajanian C; Swisher EM; Okamoto A; Steffensen KD; Bookman MA; Fleming GF; Friedlander M; Moore KN; Tewari KS; O'Malley DM; Chan JK; Ratajczak C; Hashiba H; Wu M; Dinh MH; Coleman RL
    Gynecol Oncol; 2022 Feb; 164(2):278-287. PubMed ID: 34930617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Munoz-Zuluaga CA; Sardi A; Sittig M; Gushchin V; King MC; Nieroda C; Lopez-Ramirez F; Diaz-Montes TP
    Int J Surg Oncol; 2020; 2020():1467403. PubMed ID: 33381312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance.
    Cobb LP; Sun CC; Iyer R; Nick AM; Fleming ND; Westin SN; Sood AK; Wong KK; Silva EG; Gershenson DM
    Gynecol Oncol; 2020 Sep; 158(3):653-658. PubMed ID: 32709538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
    Sioulas VD; Schiavone MB; Kadouri D; Zivanovic O; Roche KL; O'Cearbhaill R; Abu-Rustum NR; Levine DA; Sonoda Y; Gardner GJ; Leitao MM; Chi DS
    Gynecol Oncol; 2017 Apr; 145(1):15-20. PubMed ID: 28238354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
    Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
    Chan AM; Enwere E; McIntyre JB; Wilson H; Nwaroh C; Wiebe N; Ou Y; Liu S; Wiedemeyer K; Rambau PF; Grevers X; Morris DG; Neri P; Gilks CB; Visser F; Le N; Luo L; Cook LS; Köbel M
    J Pathol Clin Res; 2020 Oct; 6(4):252-262. PubMed ID: 32391646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
    Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
    Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Benefit of ≥6 Cycles of Neoadjuvant Chemotherapy for Advanced Ovarian, Tubal, and Peritoneal Cancers.
    Kondo E; Nimura R; Maki S; Kaneda M; Nii M; Yoshida K; Tabata T; Ikeda T
    Anticancer Res; 2021 Aug; 41(8):4157-4161. PubMed ID: 34281887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Chen X
    Arch Gynecol Obstet; 2017 Feb; 295(2):451-458. PubMed ID: 27913927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
    Coleridge SL; Bryant A; Kehoe S; Morrison J
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
    duPont NC; Enserro D; Brady MF; Moxley K; Walker JL; Cosgrove C; Bixel K; Tewari KS; Thaker P; Wahner Hendrickson AE; Rubin S; Fujiwara K; Casey AC; Soper J; Burger RA; Monk BJ
    Gynecol Oncol; 2022 Feb; 164(2):398-405. PubMed ID: 34857397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TP53 variant allele frequency correlates with the chemotherapy response score in ovarian/fallopian tube/peritoneal high-grade serous carcinoma.
    Lawson BC; Yang RK; Euscher ED; Ramalingam P; Malpica A
    Hum Pathol; 2021 Sep; 115():76-83. PubMed ID: 34153306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
    Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
    Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis.
    Communal L; Roy N; Cahuzac M; Rahimi K; Köbel M; Provencher DM; Mes-Masson AM
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34070214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.